Attached files

file filename
EX-10.2 - EX-10.2 - BRUKER CORPa10-12743_1ex10d2.htm
EX-10.1 - EX-10.1 - BRUKER CORPa10-12743_1ex10d1.htm
EX-31.2 - EX-31.2 - BRUKER CORPa10-12743_1ex31d2.htm
EX-31.1 - EX-31.1 - BRUKER CORPa10-12743_1ex31d1.htm
EX-32.1 - EX-32.1 - BRUKER CORPa10-12743_1ex32d1.htm
EX-10.3 - EX-10.3 - BRUKER CORPa10-12743_1ex10d3.htm

Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

x      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934

 

For the quarterly period ended June 30, 2010

 

o         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934

 

For the transition period from             to            

 

Commission File Number 000-30833

 

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

04-3110160

(State or other jurisdiction of
 incorporation or organization)

 

(I.R.S. Employer
 Identification No.)

 

40 Manning Road, Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (978) 663-3660

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x  No  o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  o  No  o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “accelerated filer, large accelerated filer, smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer o

 

Accelerated filer x

Non-accelerated filer o

 

Smaller reporting company o

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  o No  x

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class

 

Outstanding at August 3, 2010

Common Stock, $0.01 par value per share

 

164,769,064 shares

 

 

 



Table of Contents

 

BRUKER CORPORATION

 

Quarterly Report on Form 10-Q

For the Quarter Ended June 30, 2010

 

Index

 

 

 

 

 

Page

Part I

 

FINANCIAL INFORMATION

1

Item 1:

 

Unaudited Condensed Consolidated Financial Statements

1

 

 

Unaudited Condensed Consolidated Balance Sheets as of June 30, 2010 and December 31, 2009

1

 

 

Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2010 and 2009

2

 

 

Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2010 and 2009

3

 

 

Notes to Unaudited Condensed Consolidated Financial Statements

4

Item 2:

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3:

 

Quantitative and Qualitative Disclosures About Market Risk

34

Item 4:

 

Controls and Procedures

35

Part II

 

OTHER INFORMATION

35

Item 1:

 

Legal Proceedings

35

Item 1A:

 

Risk Factors

35

Item 2:

 

Unregistered Sales of Equity Securities and Use of Proceeds

36

Item 3:

 

Defaults Upon Senior Securities

36

Item 4:

 

[Removed and Reserved]

36

Item 5:

 

Other Information

36

Item 6:

 

Exhibits

36

 

 

Signatures

37

 



Table of Contents

 

PART I                FINANCIAL INFORMATION

 

ITEM 1.              UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except share data)

 

 

 

June 30,

 

December 31,

 

 

 

2010

 

2009

 

ASSETS

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

187.6

 

$

207.1

 

Restricted cash

 

2.5

 

2.0

 

Accounts receivable, net

 

161.5

 

184.1

 

Inventory

 

424.5

 

422.8

 

Other current assets

 

58.5

 

57.5

 

Total current assets

 

834.6

 

873.5

 

 

 

 

 

 

 

Property, plant and equipment, net

 

199.3

 

223.4

 

Intangibles and other long-term assets

 

106.6

 

75.1

 

Total assets

 

$

1,140.5

 

$

1,172.0

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Short-term borrowings

 

$

 

$

0.1

 

Current portion of long-term debt

 

25.1

 

21.9

 

Accounts payable

 

53.6

 

49.8

 

Customer advances

 

212.0

 

219.2

 

Other current liabilities

 

252.5

 

249.2

 

Total current liabilities

 

543.2

 

540.2

 

 

 

 

 

 

 

Long-term debt

 

101.6

 

115.7

 

Other long-term liabilities

 

83.1

 

97.3

 

Commitments and contingencies (Note 18)

 

 

 

 

 

 

 

 

 

Shareholders’ Equity:

 

 

 

 

 

Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding at June 30, 2010 and December 31, 2009

 

 

 

Common stock, $0.01 par value 260,000,000 shares authorized,  164,786,346 and 164,384,679 shares issued and 164,769,127 and 164,371,384 outstanding at June 30, 2010 and December 31, 2009, respectively

 

1.6

 

1.6

 

Treasury stock at cost, 17,219 at June 30, 2010 and 13,295 at December 31, 2009

 

(0.2

)

(0.1

)

Other shareholders’ equity

 

409.5

 

415.7

 

Total shareholders’ equity attributable to Bruker Corporation

 

410.9

 

417.2

 

Noncontrolling interest in consolidated subsidiaries

 

1.7

 

1.6

 

Total shareholders’ equity

 

412.6

 

418.8

 

 

 

 

 

 

 

Total liabilities and shareholders’ equity

 

$

1,140.5

 

$

1,172.0

 

 

The accompanying notes are an integral part of these statements.

 

1



Table of Contents

 

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

 

June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Product revenue

 

$

267.0

 

$

222.9

 

$

511.0

 

$

425.1

 

Service revenue

 

32.5

 

28.3

 

64.0

 

55.2

 

Other revenue

 

1.4

 

1.3

 

3.6

 

2.7

 

Total revenue

 

300.9

 

252.5

 

578.6

 

483.0

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

149.1

 

125.2

 

283.3

 

236.9

 

Cost of service revenue

 

16.1

 

16.1

 

33.3

 

32.2

 

Total cost of revenue

 

165.2

 

141.3

 

316.6

 

269.1

 

Gross profit

 

135.7

 

111.2

 

262.0

 

213.9

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

64.0

 

60.4

 

129.7

 

118.9

 

Research and development

 

31.2

 

31.1

 

64.0

 

60.2

 

Amortization of acquisition-related intangible assets

 

0.7

 

0.5

 

1.1

 

0.9

 

Other charges (credits), net

 

1.9

 

(1.0

)

2.4

 

(0.6

)

Total operating expenses

 

97.8

 

91.0

 

197.2

 

179.4

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

37.9

 

20.2

 

64.8

 

34.5

 

 

 

 

 

 

 

 

 

 

 

Interest and other income (expense), net

 

(4.2

)

(2.9

)

(4.5

)

(2.8

)

 

 

 

 

 

 

 

 

 

 

Income before income taxes and noncontrolling interest in consolidated subsidiaries

 

33.7

 

17.3

 

60.3

 

31.7

 

Income tax provision

 

10.8

 

4.6

 

21.4

 

10.4

 

 

 

 

 

 

 

 

 

 

 

Consolidated net income

 

22.9

 

12.7

 

38.9

 

21.3

 

Net income (loss) attributable to noncontrolling interest in consolidated subsidiaries

 

0.3

 

(0.2

)

0.2

 

 

Net income attributable to Bruker Corporation

 

$

22.6

 

$

12.9

 

$

38.7

 

$

21.3

 

 

 

 

 

 

 

 

 

 

 

Net income per common share attributable to Bruker Corporation shareholders:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.14

 

$

0.08

 

$

0.24

 

$

0.13

 

Diluted

 

$

0.14

 

$

0.08

 

$

0.23

 

$

0.13

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

164.3

 

163.3

 

164.2

 

163.3

 

Diluted

 

165.8

 

164.7

 

165.7

 

164.5

 

 

The accompanying notes are an integral part of these statements.

 

2



Table of Contents

 

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2010

 

2009

 

Cash flows from operating activities:

 

 

 

 

 

Consolidated net income

 

$

38.9

 

$

21.3

 

Adjustments to reconcile consolidated net income to cash flows from operating activities:

 

 

 

 

 

Depreciation and amortization

 

14.7

 

13.5

 

Amortization of deferred financing costs

 

0.3

 

0.3

 

Stock-based compensation

 

3.3

 

3.3

 

Deferred income taxes

 

(8.2

)

(1.8

)

Gain on bargain purchase

 

 

(2.1

)

Other non-cash expense

 

2.9

 

0.3

 

Changes in operating assets and liabilities:

 

 

 

 

 

Accounts receivable

 

9.4

 

40.3

 

Inventories

 

(37.6

)

(4.5

)

Accounts payable

 

9.3

 

(2.3

)

Customer advances

 

13.8

 

(4.7

)

Other changes in operating assets and liabilities, net

 

6.3

 

(12.3

)

Net cash provided by operating activities

 

53.1

 

51.3

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Purchases of property, plant and equipment

 

(10.7

)

(7.1

)

Acquisitions, net of cash acquired

 

(37.8

)

(1.1

)

Net cash used in investing activities

 

(48.5

)

(8.2

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Repayments of revolving lines of credit, net

 

(0.4

)

(35.8

)

Repayment of term debt

 

(9.9

)

(15.9

)

Changes in restricted cash

 

(0.7

)

(0.5

)

Issuance of common stock under stock plans

 

2.2

 

0.1

 

Cash payments to noncontrolling interests

 

(0.1

)

 

Net cash used in financing activities

 

(8.9

)

(52.1

)

Effect of exchange rate changes on cash and cash equivalents

 

(15.2

)

(4.6

)

Net change in cash and cash equivalents

 

(19.5

)

(13.6

)

Cash and cash equivalents at beginning of period

 

207.1

 

166.2

 

Cash and cash equivalents at end of period

 

$

187.6

 

$

152.6

 

 

The accompanying notes are an integral part of these statements.

 

3



Table of Contents

 

BRUKER CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1.              Description of Business

 

Bruker Corporation and its wholly-owned subsidiaries (the “Company”) is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of a diverse array of customers in life science, pharmaceutical, biotechnology and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications. The Company’s core technology platforms include X-ray technologies, magnetic resonance technologies, mass spectrometry technologies, optical emission spectroscopy and infrared and Raman molecular spectroscopy technologies. The Company also manufactures and distributes a broad range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. The Company also develops and manufactures low temperature and high temperature superconducting wire and superconducting devices for use in advanced magnet technology, physics research and energy applications. The Company maintains major technical and manufacturing centers in Europe, North America and Japan, and has sales offices located throughout the world. The Company’s diverse customer base includes life science, pharmaceutical, biotechnology and molecular diagnostic research companies, academic institutions, advanced materials and semiconductor industries and government agencies.

 

Management reports results on the basis of the following two segments:

 

·                  Scientific Instruments. The operations of this segment include the design, manufacture and distribution of advanced instrumentation and automated solutions based on X-ray technology, spark-optical emission spectroscopy technology, atomic force microscopy technology, magnetic resonance technology, mass spectrometry technology and infrared and Raman molecular spectroscopy technology. Typical customers of the Scientific Instruments segment include pharmaceutical, biotechnology, and molecular diagnostic companies; academic institutions; medical schools; other non-profit organizations; clinical microbiology laboratories; government departments and agencies; nanotechnology, semiconductor, chemical, cement, metals and petroleum companies; and food, beverage and agricultural analysis companies and laboratories.

 

·                  Energy & Supercon Technologies.  The operations of this segment include the development and marketing of superconducting and non-superconducting materials and devices for growing markets in renewable energy, energy infrastructure, healthcare and “big science” research. This segment supplies low temperature superconductors for use in magnetic resonance imaging and nuclear magnetic resonance systems, fusion energy research and other applications, as well as high temperature superconductors which are primarily used in fusion energy research. This segment also provides superconductivity-enabled devices, such as magnets, accelerator cavities and modules, radio frequency power couplers and linear accelerators, primarily for use in fusion research and other scientific applications. In addition, this segment has a number of devices and materials under development, including superconducting crystal growth magnets for photovoltaic and semiconductor applications, inductive superconducting fault current limiters for energy infrastructure applications and high temperature superconductors for compact high-power wind turbine generators and other applications. Typical customers of the Energy & Supercon Technologies segment include manufacturers of medical technology and life science analytics tools and universities and dedicated research facilities in the fields of material sciences, energy, biotechnology and proteomics, among others.

 

The financial statements represent the consolidated accounts of the Company. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2010 and 2009 have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial information presented herein does not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation have been included. The results for interim periods are not necessarily indicative of the results expected for the full year. Certain prior year amounts have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net income or shareholders’ equity.

 

4



Table of Contents

 

2.              Acquisitions

 

On May 19, 2010, the Company completed the acquisition of three former Varian, Inc. (“Varian”), product lines which Agilent Technologies, Inc. (“Agilent”) divested in connection with obtaining regulatory approval for its May 14, 2010 acquisition of Varian. The Company acquired certain assets and assumed certain liabilities in Varian’s inductively coupled plasma mass spectrometry instruments business, laboratory gas chromatography instruments business, and gas chromatography triple-quadrupole mass spectrometry instruments business (collectively, the “chemical analysis business”) for cash consideration of $37.5 million. The acquired business complements the Company’s existing mass spectrometry products and expands the Company’s offerings to industrial and applied markets. The acquisition of the chemical analysis business is being accounted for under the acquisition method. The Company has not yet completed the final allocation of the purchase price but has preliminarily allocated the consideration transferred as follows:

 

Inventory

 

$

13.0

 

Property, plant and equipment

 

2.8

 

Intangible assets

 

9.7

 

Goodwill

 

22.0

 

Liabilities assumed

 

(10.0

)

 

 

$

37.5

 

 

The allocation of the purchase price will be completed within the measurement period.

 

The results of the chemical analysis business have been included in the Scientific Instruments segment from the date of acquisition. Pro forma financial information reflecting the acquisition of the chemical analysis business has not been presented because the impact on revenues, net income and net income per common share attributable to Bruker Corporation shareholders is not material.

 

In April 2009, the Company acquired substantially all of the assets of the research instruments portion of ACCEL Instruments GmbH (the “RI business”) from Varian Medical Systems, Inc. The acquisition of the RI business was accounted for under the acquisition method. The RI business, located in Bergisch Gladbach, Germany, consists of the development and manufacture of electron and ion linear accelerators, superconducting and normal conducting accelerator cavities, insertion devices, superconducting fault current limiters, other accelerator components and specialty superconducting magnets for physics and energy research and a variety of other scientific applications. The consideration transferred in acquiring the RI business was approximately $0.4 million and consisted entirely of cash. The Company acquired approximately $2.8 million of receivables, $4.4 million of inventory, $2.2 million of other current assets and $4.9 million of property, plant and equipment in this acquisition and assumed approximately $12.1 million of current liabilities. The Company also recorded $0.5 million representing the fair value of a noncontrolling interest. In 2009, in connection with the acquisition of the RI business, the Company recorded a gain of approximately $1.3 million that was recorded as a component of acquisition-related charges in the consolidated statements of operations. A gain of $2.1 million was initially recorded in the second quarter of 2009 based on a preliminary purchase price allocation, but was subsequently reduced by $0.8 million in the fourth quarter of 2009 based on the final allocation. The results of the RI business have been included in the Energy & Supercon Technologies segment from the date of acquisition. Pro forma financial information reflecting the acquisition of the RI business has not been presented because the impact on revenues, net income and net income per common share attributable to Bruker Corporation shareholders is not material.

 

3.              Stock-Based Compensation

 

The Company’s primary types of share-based compensation are in the form of stock options and restricted stock. The Company recorded stock-based compensation expense for the three and six months ended June 30, 2010 and 2009 as follows (in millions):

 

5



Table of Contents

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Stock options

 

$

1.5

 

$

1.2

 

$

2.8

 

$

2.5

 

Restricted stock

 

0.2

 

0.3

 

0.5

 

0.8

 

Total stock-based compensation, pre-tax

 

1.7

 

1.5

 

3.3

 

3.3

 

Tax benefit

 

0.2

 

0.2

 

0.5

 

0.6

 

Total stock-based compensation, net of tax

 

$

1.5

 

$

1.3

 

$

2.8

 

$

2.7

 

 

Compensation expense is amortized on a straight-line basis over the underlying vesting terms. Stock options to purchase the Company’s common stock are periodically awarded to executive officers and other employees of the Company subject to a vesting period of three to five years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. Assumptions regarding volatility, expected life, dividend yield and risk-free interest rate are required for the Black-Scholes model and are presented in the table below:

 

 

 

2010

 

2009

 

Risk-free interest rate

 

2.42%-3.46%

 

1.71%-3.60%

 

Expected life

 

6.5 years

 

6.5 years

 

Volatility

 

62.0

%

64.0

%

Expected dividend yield

 

0.0

%

0.0

%

 

The risk-free interest rate is the yield on zero-coupon U.S. Treasury securities for a period that is commensurate with the expected life assumption. Expected life is determined through the simplified method as defined in the Securities and Exchange Commission Staff Accounting Bulletin No. 110. The Company believes that this is the best estimate of the expected life of a new option. Expected volatility can be based on a number of factors but the Company currently believes that the exclusive use of historical volatility results in the best estimate of the grant-date fair value of employee stock options because it reflects the market’s current expectations of future volatility. Expected dividend yield was not considered in the option pricing formula since the Company does not pay dividends and has no current plans to do so in the future. The terms of some of the Company’s indebtedness also currently restrict its ability to pay dividends to its shareholders.

 

Bruker Corporation Stock Plan

 

In February 2010, the Bruker BioSciences Corporation Amended and Restated 2000 Stock Option Plan (the “2000 Plan”) expired at the end of its scheduled ten-year term. On March 9, 2010, the Company’s Board of Directors unanimously approved and adopted the Bruker Corporation 2010 Incentive Compensation Plan (the “2010 Plan”) and on May 14, 2010, the 2010 Plan was approved by the Company’s stockholders. The 2010 Plan provides for the issuance of up to 8,000,000 shares of the Company’s common stock. The Plan allows a committee of the Board of Directors (the “Committee”) to grant incentive stock options, non-qualified stock options and restricted stock awards. The Committee has the authority to determine which employees will receive the awards, the amount of the awards and other terms and conditions of the award. Awards granted by the Committee typically vest over a period of three to five years.

 

At June 30, 2010, the Company expects to recognize pre-tax stock-based compensation expense of $12.6 million associated with outstanding stock option awards granted under the Company’s stock plans over the weighted average remaining service period of 1.8 years. In addition, the Company expects to recognize additional pre-tax stock-based compensation expense of $1.9 million associated with outstanding restricted stock awards granted under the Plan over the weighted average remaining service period of one year.

 

Bruker Energy & Supercon Technologies Stock Plan

 

In October 2009, the Board of Directors of Bruker Energy & Supercon Technologies, Inc. (“BEST”), a wholly-owned direct subsidiary of the Company, adopted the Bruker Energy & Supercon Technologies, Inc. 2009 Stock Option Plan (the “BEST Plan”). The BEST Plan provides for the issuance of up to 1,600,000 shares of BEST common stock in connection with awards under the Plan. The Plan allows a committee of the BEST Board of Directors to grant incentive stock options and non-qualified stock options.

 

At June 30, 2010, the Company expects to recognize pre-tax stock-based compensation expense of $1.5 million associated

 

6



Table of Contents

 

with outstanding stock option awards granted under the BEST Plan over the weighted average remaining service period of 4.3 years.

 

4.              Earnings Per Share

 

Net income per share is calculated by dividing net income by the weighted-average shares outstanding during the period. The diluted net income per share computation includes the effect of shares which would be issuable upon the exercise of outstanding stock options and the vesting of restricted stock, reduced by the number of shares, which are assumed to be purchased by the Company from the resulting proceeds at the average market price during the period.

 

The following table sets forth the computation of basic and diluted average shares outstanding for the three and six months ended June 30, 2010 and 2009 (in millions, except per share amounts):

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Net income attributable to Bruker Corporation

 

$

22.6

 

$

12.9

 

$

38.7

 

$

21.3

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding-basic

 

164.3

 

163.3

 

164.2

 

163.3

 

Effect of dilutive securities:

 

 

 

 

 

 

 

 

 

Stock options and restricted stock

 

1.5

 

1.4

 

1.5

 

1.2

 

 

 

165.8

 

164.7

 

165.7

 

164.5

 

 

 

 

 

 

 

 

 

 

 

Net income per common share attributable to Bruker Corporation shareholders:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.14

 

$

0.08

 

$

0.24

 

$

0.13

 

Diluted

 

$

0.14

 

$

0.08

 

$

0.23

 

$

0.13

 

 

Stock options to purchase approximately 0.4 million shares and 3.3 million shares were excluded from the computation of diluted earnings per share in the three months ended June 30, 2010 and 2009, respectively, and approximately 0.4 million shares and 3.5 million shares were excluded from the computation of diluted earnings per share in the six months ended June 30, 2010 and 2009, respectively, because the exercise price of the stock options exceeded the average market price of the Company’s common stock and, as a result, would have had an anti-dilutive effect.

 

5.              Fair Value of Financial Instruments

 

The Company applies the following hierarchy, which prioritizes the input used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The three levels are defined as follows:

 

Level 1:     Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2:     Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

Level 3:     Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company measures the following financial assets and liabilities at fair value on a recurring basis. The fair value of these financial assets and liabilities was determined using the following inputs at June 30, 2010 (in millions):

 

7



Table of Contents

 

 

 

 

 

Quoted Prices
in Active
Markets
Available

 

Significant
Other
Observable
Inputs

 

Significant
Unobservable
Inputs

 

 

 

Total

 

(Level 1)

 

(Level 2)

 

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

93.1

 

$

93.1

 

$

 

$

 

Embedded Derivatives in Purchases and Delivery Contracts

 

0.3

 

 

0.3

 

 

Total assets recorded at fair value

 

$

93.4

 

$

93.1

 

$

0.3

 

$

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

Interest rate swap

 

$

3.7

 

$

 

$

3.7

 

$

 

Embedded derivatives in purchase and delivery contracts

 

4.1

 

 

4.1

 

 

Foreign exchange contracts

 

1.3

 

 

1.3

 

 

Total liabilities recorded at fair value

 

$

9.1

 

$

 

$

9.1

 

$

 

 

The Company’s financial instruments consist primarily of cash equivalents, derivative instruments consisting of forward contracts, options and an interest rate swap, accounts receivable, short-term borrowings, accounts payable and long-term debt. The carrying amounts of the Company’s cash equivalents, accounts receivable, short-term borrowings and accounts payable approximate fair value due to their short-term nature. Derivative assets and liabilities are measured at fair value on a recurring basis. The fair value of derivative instruments is based on quotes received from third party banks. These values represent the estimated amount the Company would receive or pay to terminate the agreements taking into consideration current foreign exchange or interest rates, as well as the creditworthiness of the counterparty. The Company’s long-term debt consists primarily of variable rate arrangements with interest rates that reset every three months and, as a result, reflect current interest rates. Consequently, the carrying value of the Company’s long-term debt approximates fair value.

 

6.              Inventories

 

Inventories consisted of the following as of June 30, 2010 and December 31, 2009 (in millions):

 

 

 

June 30,
2010

 

December 31,
2009

 

Raw materials

 

$

115.2

 

$

108.8

 

Work-in-process

 

149.6

 

134.6

 

Demonstration units

 

40.7

 

41.3

 

Finished goods

 

119.0

 

138.1

 

Inventories

 

$

424.5

 

$

422.8

 

 

The Company reduces the carrying value of its demonstration inventories for differences between its cost and estimated net realizable value through a charge to cost of revenue that is based on a number of factors including the age of the unit, the physical condition of the unit and an assessment of technological obsolescence. Amounts recorded in cost of product revenue related to the write-down of demonstration units to net realizable value were $5.6 million and $6.1 million for the three months ended June 30, 2010 and 2009, respectively and $11.2 million and $11.9 million for the six months ended June 30, 2010 and 2009, respectively.

 

Finished goods include in-transit systems that have been shipped to the Company’s customers but have not yet been installed and accepted by the customer. As of June 30, 2010 and December 31, 2009, inventory-in-transit was $57.7 million and $80.8 million, respectively.

 

7.              Goodwill and Other Intangible Assets

 

The following table sets forth the changes in the carrying amount of goodwill for the six months ended June 30, 2010 (in millions):

 

8



Table of Contents

 

Balance at December 31, 2009

 

$

47.5

 

Goodwill acquired during the period

 

22.3

 

Foreign currency impact

 

(3.6

)

Balance at June 30, 2010

 

$

66.2

 

 

Goodwill is not amortized, instead, goodwill is tested for impairment on a reporting unit basis annually, or on an interim basis when events or changes in circumstances warrant. The Company performed its annual test for impairment as of December 31, 2009 and determined that goodwill and other intangible assets were not impaired at that time. The Company did not identify any indicators of impairment during the six month period ended June 30, 2010.

 

The following is a summary of other intangible assets subject to amortization at June 30, 2010 and December 31, 2009 (in millions):

 

 

 

June 30, 2010

 

December 31, 2009

 

 

 

Gross
Carrying
Amount

 

Accumulated
Amortization

 

Net Carrying
Amount

 

Gross
Carrying
Amount

 

Accumulated
Amortization

 

Net Carrying
Amount

 

Existing technology and related patents

 

$

19.4

 

$

(11.4

)

$

8.0

 

$

14.4

 

$

(10.7

)

$

3.7

 

Customer relationships

 

5.9

 

(1.4

)

4.5

 

2.0

 

(0.9

)

1.1

 

Trade names

 

0.7

 

(0.3

)

0.4

 

0.4

 

(0.3

)

0.1

 

Intangible assets subject to amortization, net

 

$

26.0

 

$

(13.1

)

$

12.9

 

$

16.8

 

$

(11.9

)

$

4.9

 

 

For the three months ended June 30, 2010 and 2009, the Company recorded amortization expense of $0.7 million and $0.5 million, respectively, related to intangible assets subject to amortization. For the six months ended June 30, 2010 and 2009, the Company recorded amortization expense of $1.2 million and $0.9 million, respectively, related to intangible assets subject to amortization.

 

8.              Debt

 

At June 30, 2010 and December 31, 2009, the Company’s debt obligations consisted of the following (in millions):

 

 

 

June 30,

 

December 31,

 

 

 

2010

 

2009

 

US Dollar term loan under the Credit Agreement

 

$

121.9

 

$

131.3

 

 

 

 

 

 

 

Euro bank loans at fixed rate of 2.95%, collateralized by land and buildings of Bruker Daltonik GmbH, quarterly principal payments and monthly interest payments due and payable through 2010

 

 

0.3

 

 

 

 

 

 

 

Capital lease obligations

 

4.8

 

6.0

 

Total long-term debt

 

126.7

 

137.6

 

Current portion of long-term debt

 

(25.1

)

(21.9

)

Total long-term debt, less current portion

 

$

101.6

 

$

115.7

 

 

In 2008, the Company entered into a credit agreement with a syndication of lenders (the “Credit Agreement”) which provides for a revolving credit line with a maximum commitment of $230.0 million and a term facility of $150.0 million. The outstanding principal and interest under the term loan is payable in quarterly installments through December 2012. Borrowings under the Credit Agreement bear interest, at the Company’s option, at either (i) the higher of the prime rate or the federal funds rate plus 0.50%, or (ii) adjusted LIBOR, plus margins ranging from 0.40% to 1.25% and a facility fee ranging from 0.10% to 0.20%. As of June 30, 2010, the weighted average interest rate of borrowings under the term facility of the Credit Agreement was approximately 2.7%.

 

Borrowings under the Credit Agreement are secured by the pledge to the banks of 100% of the capital stock of each of the Company’s wholly-owned domestic subsidiaries and 65% of the capital stock of certain of the Company’s direct or indirect wholly-owned foreign subsidiaries. The Credit Agreement also requires the Company to maintain certain financial ratios related to leverage ratios and interest coverage ratios as defined in the Credit Agreement. In addition to the financial ratios, the

 

9



Table of Contents

 

Credit Agreement restricts, among other things, the Company’s ability to do the following: make certain payments; incur additional debt; incur certain liens; make certain investments, including derivative agreements; merge, consolidate, sell or transfer all or substantially all of the Company’s assets; and enter into certain transactions with affiliates. As of June 30, 2010, the latest measurement date, the Company was in compliance with the covenants under the Credit Agreement.

 

In addition to its long-term arrangements, the Company had the following amounts outstanding under revolving loan arrangements:

 

 

 

June 30,

 

December 31,

 

 

 

2010

 

2009

 

Revolving loans under the Credit Agreement

 

$

 

$

 

Other revolving loans

 

 

0.1

 

Total short-term borrowings

 

$

 

$

0.1

 

 

The following is a summary of the maximum commitments and net amounts available to the Company under revolving loans as of June 30, 2010 (in millions):

 

 

 

Weighted
Average
Interest Rate

 

Total Amount
Committed by
Lenders

 

Outstanding
Borrowings

 

Outstanding
Letters of
Credit

 

Total Amount
Available

 

Credit Agreement

 

%

$

230.0

 

$

 

$

1.4

 

$

228.6

 

Other revolving loans

 

%

90.7

 

 

76.5

 

14.2

 

Total revolving loans

 

 

 

$

320.7

 

$

 

$

77.9

 

$

242.8

 

 

Other revolving loans are with various financial institutions located primarily in Germany, Switzerland and France. The Company’s other revolving lines of credit are typically due upon demand with interest payable monthly. Certain of these lines of credit are unsecured while others are secured by the accounts receivable and inventory of the related subsidiary.

 

9.              Derivative Instruments and Hedging Activities

 

Interest Rate Risks

 

The Company’s exposure to interest rate risk relates primarily to outstanding variable rate debt and adverse movements in the related short-term market rates. The most significant component of the Company’s interest rate risk relates to amounts outstanding under the Credit Agreement. In April 2008, the Company entered into an interest rate swap arrangement to manage its exposure to interest rate movements and the related effect on its variable rate debt. Under this interest rate swap arrangement, the Company will pay a fixed rate of approximately 3.8% and receive a variable rate based on three month LIBOR. The initial notional amount of this interest rate swap was $90.0 million and it amortizes in proportion to the term debt component of the Credit Agreement through December 2012. At June 30, 2010, the notional amount of this interest rate swap was $73.1 million. The Company concluded that this swap met the criteria to qualify as an effective hedge of the variability of cash flows of the interest payments and accounts for the interest rate swap as a cash flow hedge. Accordingly, the Company reflects changes in the fair value of the effective portion of this interest rate swap in accumulated other comprehensive income, a component of shareholders’ equity. As of June 30, 2010 and December 31, 2009, the Company recorded a liability of $3.7 million and $3.5 million, respectively, related to the fair value of the interest rate swap that is recorded in other current liabilities in the consolidated balance sheets. Amounts recorded in accumulated other comprehensive income (loss) are reclassified to interest and other income (expense), net in the consolidated statement of operations when either the forecasted transaction occurs or it becomes probable that the forecasted transaction will not occur. The Company expects $2.2 million of the accumulated loss to be reclassified into earnings over the next twelve months.

 

Foreign Exchange Rate Risk Management

 

The Company generates a substantial portion of its revenues and expenses in international markets, principally Europe and Japan, which subjects its operations to the exposure of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company, from time to time, has entered into foreign currency contracts in order to minimize the volatility that fluctuations in currency exchange rates have on the Company’s cash flows

 

10



Table of Contents

 

related to purchases and sales denominated in foreign currencies.

 

The Company periodically enters into foreign currency contracts, primarily forward and option contracts, to minimize the volatility that fluctuations in currency exchange rates have on the Company’s cash flows related to purchases and sales denominated in foreign currencies. Under these arrangements, the Company typically agrees to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. Dollars or other currencies on specified dates with maturities of less than two years. These transactions do not qualify for hedge accounting and, accordingly, the instrument is recorded at fair value with the corresponding gains and losses recorded in interest and other income (expense), net in the consolidated statements of operations. At June 30, 2010, and December 31, 2009, the following foreign currency contracts were outstanding:

 

 

 

 

 

Notional Amount

 

Buy

 

Sell

 

June 30,
2010

 

December 31,
2009

 

Euro

 

U.S. Dollars

 

$

20.8

 

$

5.5

 

Swiss Francs

 

U.S. Dollars

 

12.6

 

13.1

 

Japanese Yen

 

Euro

 

0.1

 

 

U.S. Dollars

 

Euro

 

 

6.7

 

 

 

 

 

$

33.5

 

$

25.3

 

 

In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $35.8 million for the delivery of products and $0.2 million for the purchase of products at June 30, 2010 and $30.4 million for the delivery of products and $0.2 million for the purchase of products at December 31, 2009. The changes in the fair value of these embedded derivatives are recorded in interest and other income (expense), net in the consolidated statements of operations.

 

The fair value of the foreign exchange derivative instruments described above is recorded in our consolidated balance sheets for the periods ended June 30, 2010 and December 31, 2009 as follows (in millions):

 

 

 

 

 

Fair Value

 

 

 

Balance Sheet Location

 

June 30,
2010

 

December 31,
2009

 

Derivative assets:

 

 

 

 

 

 

 

Embedded derivatives in purchase and delivery contracts

 

Other current assets

 

$

0.3

 

$

 

Foreign exchange contracts

 

Other current assets

 

 

 

 

 

 

 

 

 

 

 

Derivative liabilities:

 

 

 

 

 

 

 

Interest rate swap contract

 

Other current liabilities

 

$

3.7

 

$

3.5

 

Embedded derivatives in purchase and delivery contracts

 

Other current liabilities

 

4.1

 

1.5

 

Foreign exchange contracts

 

Other current liabilities

 

1.3

 

 

 

The losses recognized in other comprehensive income related to the effective portion of the interest rate swap designated as a hedging instrument for the three and six months ended June 30, 2010 and 2009 are as follows (in millions):

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Interest rate swap contract

 

$

(0.6

)

$

0.5

 

$

(1.5

)

$

0.1

 

 

The losses related to the effective portion of the interest rate swap designated as a hedging instrument that were reclassified from other comprehensive income and recognized in net income for the three and six months ended June 30, 2010 and 2009 are as follows (in millions):

 

11



Table of Contents

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Interest rate swap contract

 

$

(0.7

)

$

(0.6

)

$

(1.4

)

$

(1.1

)

 

The Company did not recognize any amounts related to ineffectiveness in the results of operations for the three and six months ended June 30, 2010 and 2009.

 

The impact on net income of changes in the fair value of derivative instruments not designated as hedging instruments for the three and six months ended June 30, 2010 and 2009 are as follows (in millions):

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Foreign exchange contracts

 

$

(1.1

)

$

(0.3

)

$

(1.3

)

$

 

Embedded derivatives in purchase and delivery contracts

 

(1.6

)

(1.0

)

(2.3

)

0.6

 

Income (expense), net

 

$

(2.7

)

$

(1.3

)

$

(3.6

)

$

0.6

 

 

The amounts recorded in the results of operations related to derivative instruments not designated as hedging instruments are recorded in interest and other income (expense), net.

 

10.       Other Charges (Credits), Net

 

The components of other charges (credits), net, were as follows for the three and six months ended June 30, 2010 and 2009 (in millions):

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

 

 

 

 

 

 

 

 

 

 

Acquisition-related charges

 

$

0.4

 

$

0.4

 

$

0.7

 

$

0.8

 

Transition-related charges incurred in connection with acquired businesses

 

0.5

 

 

0.5

 

 

Loss on divestiture of businesses

 

1.0

 

 

1.0

 

 

Restructuring charges (Note 11)

 

 

 

0.2

 

 

Impairment charges (Note 12)

 

 

0.7

 

 

0.7

 

Gain on bargain purchase (Note 2)

 

 

(2.1

)

 

(2.1

)

Other charges (credits), net

 

$

1.9

 

$

(1.0

)

$

2.4

 

$

(0.6

)

 

11.       Restructuring Charges

 

In the first quarter of 2010, the Company recorded restructuring charges of $0.2 million, which related primarily to severance incurred in connection with the closing of a production facility in Herzogenrath, Germany and relocating the associated operations. These charges were recorded in the Scientific Instruments segment. The Company does not expect to incur any additional costs related to this move and expects to have made all of the severance payments by the end of the 2010. The liability for restructuring charges is recorded in other current liabilities in the unaudited condensed consolidated balance sheets. The charges related to this restructuring reserve are as follows (in millions):

 

12



Table of Contents

 

 

 

Total

 

Severance

 

Balance at December 31, 2009

 

$

 

$

 

Restructuring charges

 

0.2

 

0.2

 

Cash payments

 

 

 

Foreign currency impact

 

 

 

Balance at June 30, 2010

 

$

0.2

 

$

0.2

 

 

12.       Impairment Charges

 

In the second quarter of 2009, the Company recorded an impairment charge of $0.7 million, which consisted of certain fixed assets used in the production of certain superconducting wire. The impairment loss was recorded because the Company determined that the carrying value of the assets exceeded their fair value based on the estimated undiscounted operating cash flows generated by those assets. The impairment charge was allocated to the Energy & Supercon Technologies segment and has been recorded as a component of other charges (credits), net in the unaudited condensed consolidated statements of operations.

 

13.       Employee Benefit Plans

 

Substantially all of the Company’s employees in Switzerland, France and Japan, as well as certain employees in Germany, are covered by Company-sponsored defined benefit pension plans. Retirement benefits are generally earned based on years of service and compensation during active employment. Eligibility is generally determined in accordance with local statutory requirements; however, the level of benefits and terms of vesting varies among plans.

 

The net periodic pension cost consists of the following components for the three and six months ended June 30, 2010 and 2009 (in millions):

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Components of net periodic benefit costs:

 

 

 

 

 

 

 

 

 

Service cost

 

$

1.1

 

$

1.1

 

$

2.0

 

$

2.0

 

Interest cost

 

1.3

 

1.0

 

2.5

 

2.0

 

Expected return on plan assets

 

(0.9

)

(1.0

)

(1.8

)

(1.9

)

Amortization of prior service costs

 

0.2

 

 

0.5

 

 

Net periodic benefit costs

 

$

1.7

 

$

1.1

 

$

3.2

 

$

2.1

 

 

The Company made contributions of $1.3 million to its defined benefit plans during the six months ended June 30, 2010 and estimates contributions of $1.3 million will be made during the remainder of 2010.

 

14.       Interest and Other Income (Expense), Net

 

The components of interest and other income (expense), net, were as follows for the three and six months ended June 30, 2010 and 2009 (in millions):

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Interest income

 

$

0.2

 

$

0.4

 

$

0.3

 

$

0.8

 

Interest expense

 

(1.3

)

(2.1

)

(2.8

)

(4.4

)

Exchange gains (losses) on foreign currency transactions

 

(2.4

)

(0.7

)

(1.9

)

0.6

 

Other

 

(0.7

)

(0.5

)

(0.1

)

0.2

 

Interest and other income (expense), net

 

$

(4.2

)

$

(2.9

)

$

(4.5

)

$

(2.8

)

 

15.       Provision for Income Taxes

 

The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and

 

13



Table of Contents

 

liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. In addition, the Company also accounts for uncertain tax positions that have reached a minimum recognition threshold.

 

The income tax provision for the three months ended June 30, 2010 and 2009 was $10.8 million and $4.6 million, respectively, representing effective tax rates of 32.0% and 26.6%, respectively. The income tax provision for the six months ended June 30, 2010 and 2009 was $21.4 million and $10.4 million, respectively, representing effective tax rates of 35.5% and 32.8%, respectively. The Company’s effective tax rate generally reflects the tax provision (benefit) for non-U.S. entities only, since no benefit was recognized for cumulative losses incurred in the U.S. A full valuation allowance will be maintained against all U.S. deferred tax assets, including U.S. net operating losses and tax credits, until evidence exists that it is more likely than not that the loss carryforward and credit amounts will be utilized to offset U.S. taxable income. The Company’s tax rate may change over time as the amount or mix of income and taxes outside the U.S. changes. The effective tax rate is calculated using projected annual pre-tax income or loss and is affected by research and development tax credits, the expected level of other tax benefits, the impact of changes to the valuation allowance, and changes in the mix of the Company’s pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

 

The Company has unrecognized tax benefits of approximately $24.3 million as of June 30, 2010, of which $15.9 million, if recognized, would result in a reduction of the Company’s effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of June 30, 2010 and December 31, 2009, approximately $4.3 million and $3.8 million, respectively, of accrued interest and penalties related to uncertain tax positions was included in other current liabilities on the unaudited condensed consolidated balance sheets. Penalties and interest related to unrecognized tax benefits in the provision for income taxes of $0.3 million and $0.2 million were recorded during the three months ended June 30, 2010 and 2009, respectively, and $0.5 million and $0.4 million were recorded during the six months ended June 30, 2010 and 2009, respectively.

 

The Company files returns in many foreign and state jurisdictions with varying statutes of limitations, but considers its significant tax jurisdictions to include the United States, Germany and Switzerland. The tax years 2003 to 2009 are open tax years in these major taxing jurisdictions. One of the Company’s Swiss entities is currently being audited for the tax years 2003 through 2006 and the audit is expected to be completed during 2010. In addition, a majority of the Company’s German subsidiaries are under tax audit for the years 2003 through 2008. The Company cannot reasonably predict the timing or outcome of these audits.

 

16.       Accumulated Other Comprehensive Income (Loss)

 

Comprehensive income (loss) refers to revenues, expenses, gains and losses that under GAAP are included in other comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity, net of tax. The following is a summary of comprehensive income (loss) for the three and six months ended June 30, 2010 and 2009 (in millions):

 

14



Table of Contents

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Consolidated net income

 

$

22.9

 

$

12.7

 

$

38.9

 

$

21.3

 

Foreign currency translation adjustments

 

(30.7

)

22.7

 

(50.7

)

(3.7

)

Unrealized gains (losses) on interest rate swap:

 

 

 

 

 

 

 

 

 

Unrealized holding gains (losses) arising during the period

 

(0.6

)

0.5

 

(1.5

)

0.1

 

Less reclassification adjustments for settlements included in the determination of net income (loss)

 

0.7

 

0.6

 

1.4

 

1.1

 

Pension liability adjustments

 

0.3

 

 

0.4

 

1.0

 

Total comprehensive income (loss)

 

(7.4

)

36.5

 

(11.5

)

19.8

 

Less: Comprehensive income (loss) attributable to noncontrolling interests

 

0.3

 

(0.2

)

0.2

 

 

Comprehensive income (loss) attributable to Bruker Corporation

 

$

(7.7

)

$

36.7

 

$

(11.7

)

$

19.8

 

 

17.       Noncontrolling Interests

 

Net income (loss) attributable to noncontrolling interests for the three months ended June 30, 2010 and 2009 was $0.3 million and $(0.2) million, respectively. Net income (loss) attributable to noncontrolling interests for the six months ended June 30, 2010 and 2009 was $0.2 million and $0.0 million, respectively. The net income (loss) attributable to noncontrolling interests represents the minority shareholders’ proportionate share of the net loss recorded by five majority-owned indirect subsidiaries, Bruker Baltic Ltd., Bruker Labmate Pvt. Ltd., InCoaTec GmbH and Perch Solutions OY, which are included in the Scientific Instruments segment, and RI Research Instruments GmbH, which is included in the Energy & Supercon Technologies segment.

 

In the second quarter of 2010, the Company sold its ownership interest in Bruker Baltic Ltd. to one of its minority shareholders as part of its efforts to consolidate production. In addition, the Company made a payment of $0.1 million to the minority shareholders of RI Research Instruments GmbH during the second quarter of 2010.

 

18.       Commitments and Contingencies

 

Legal

 

Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. The Company believes the outcome of these proceedings, if any, will not have a material impact on the Company’s financial position or results of operations. As of June 30, 2010 and December 31, 2009, no accruals have been recorded for such potential contingencies.

 

Letters of Credit and Guarantees

 

At June 30, 2010 and December 31, 2009, the Company had bank guarantees of $77.9 million and $87.0 million, respectively, for its customer advances. These arrangements guarantee the refund of advance payments received from customers in the event that the merchandise is not delivered in compliance with the terms of the contract. Certain of these guarantees affect the availability of the Company’s lines of credit.

 

19.       Business Segment Information

 

The Company’s reportable segments are organized by the types of products and services provided. The Company has combined the Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics operating segments into the Scientific Instruments reporting segment because each has similar economic characteristics, product processes and services, types and classes of customers, methods of distribution and regulatory environments.

 

15



Table of Contents

 

Management evaluates segment operating performance and allocates resources based on operating income (loss). The Company uses this measure because it helps provide an understanding of our core operating results. Selected business segment information is presented below for the three and six months ended June 30, 2010 and 2009 (in millions):

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2010

 

2009

 

2010

 

2009

 

Revenue:

 

 

 

 

 

 

 

 

 

Scientific Instruments

 

$

284.9

 

$

241.3

 

$

545.2

 

$

464.9

 

Energy & Supercon Technologies

 

18.1

 

13.7

 

38.8

 

21.8

 

Eliminations (a)

 

(2.1

)

(2.5

)

(5.4

)

(3.7

)

Total revenue

 

$

300.9

 

$

252.5

 

$

578.6

 

$

483.0

 

 

 

 

 

 

 

 

 

 

 

Operating Income (Loss):

 

 

 

 

 

 

 

 

 

Scientific Instruments

 

$

40.4

 

$

20.4

 

$

68.1

 

$

36.5

 

Energy & Supercon Technologies

 

(1.7

)

(0.7

)

(2.2

)

(3.1

)

Corporate, eliminations and other (b)

 

(0.8

)

0.5

 

(1.1

)

1.1

 

Total operating income

 

$

37.9

 

$

20.2

 

$

64.8

 

$

34.5

 

 


(a) Represents product and service revenue between reportable segments.

(b) Represents corporate costs and eliminations not allocated to the reportable segments.

 

Total assets by segment as of June 30, 2010 and December 31, 2009 are as follows (in millions):

 

 

 

June 30,

 

December 31,

 

 

 

2010

 

2009

 

Assets:

 

 

 

 

 

Scientific Instruments

 

$

1,120.4

 

$

1,139.7

 

Energy & Supercon Technologies

 

59.6

 

70.3

 

Eliminations and other (a)

 

(39.5

)

(38.0

)

Total assets

 

$

1,140.5

 

$

1,172.0

 

 


(a) Assets not allocated to the reportable segments and eliminations of intercompany transactions.

 

20.       Recent Accounting Pronouncements

 

In September 2009, the Emerging Issues Task Force reached consensus on FASB Accounting Standards Update 2009-14, Software (Topic 985)—Certain Revenue Arrangements That Include Software Elements. FASB Accounting Standards Updates 2009-14 changes the accounting model for revenue arrangements that include both tangible products and software elements. Under this guidance, tangible products containing software components and non-software components that function together to deliver the tangible product’s essential functionality are excluded from the software revenue guidance in Subtopic 985-605,  Software-Revenue Recognition. In addition, hardware components of a tangible product containing software components are always excluded from the software revenue guidance. FASB Accounting Standards Updates 2009-14 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, however, early adoption is permitted. The Company is currently assessing the impact that this update will have on its results of operations and financial position and when the Company will adopt these requirements.

 

In September 2009, the Emerging Issues Task Force reached consensus on FASB Accounting Standards Update 2009-13, Revenue Recognition (Topic 605)—Multiple-Deliverable Revenue Arrangements. FASB Accounting Standards Update 2009-13 addresses the accounting for multiple-deliverable arrangements to enable vendors to account for products or services separately rather than as a combined unit. Specifically, this guidance amends the criteria in Subtopic 605-25, Revenue Recognition-Multiple-Element Arrangements, for separating consideration in multiple-deliverable arrangements. This guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence; (b) third-party evidence; or (c) estimates. This guidance also eliminates the residual method of allocation and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. In addition, this guidance significantly expands required disclosures related to a vendor’s multiple-deliverable revenue arrangements. FASB Accounting Standards Update 2009-13 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, however, early

 

16



Table of Contents

 

adoption is permitted. The Company is currently assessing the impact that this update will have on its results of operations and financial position and when the Company will adopt these requirements.

 

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2009.

 

Statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations, which express that we “believe,” “anticipate,” “plan,” “expect,” “seek,” “estimate,” or “should,” as well as other statements, which are not historical fact, are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. Actual events or results may differ materially from those set forth in forward-looking statements. Certain factors that might cause such a difference are discussed in “Factors Affecting Our Business, Operating Results and Financial Condition” set forth in our Annual Report on Form 10-K for the year ended December 31, 2009.

 

OVERVIEW

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, describes the principal factors affecting the results of our operations, financial condition and changes in financial condition, as well as our critical accounting policies and estimates. Our MD&A is organized as follows:

 

·                  Executive overview. This section provides a general description and history of our business, a brief discussion of our reportable segments, significant recent developments in our business and other opportunities, challenges we face and risks that may impact our business in the future.

 

·                  Critical accounting policies. This section discusses the accounting estimates that are considered important to our financial position and results of operations and that require us to exercise subjective or complex judgments in their application.

 

·                  Results of operations. This section provides our analysis of the significant line items on our unaudited condensed consolidated statement of operations for the three and six months ended June 30, 2010 compared to the three and six months ended June 30, 2009.

 

·                  Liquidity and capital resources. This section provides an analysis of our liquidity and cash flow and discussions of our outstanding debt and commitments and matters relating to our common stock.

 

·                  Recent accounting pronouncements. This section provides information about new accounting standards that have been issued but for which adoption is not yet required.

 

EXECUTIVE OVERVIEW

 

Business Overview

 

Bruker Corporation and its wholly-owned subsidiaries design, manufacture, service and market proprietary life science and materials research systems based on its core technology platforms, including X-ray technologies, magnetic resonance technologies, mass spectrometry technologies, optical emission spectroscopy and infrared and Raman molecular spectroscopy technologies. We sell a broad range of field analytical systems for chemical, biological, radiological, nuclear and explosive, or CBRNE, detection. We also develop and manufacture low temperature and high temperature superconducting wire products and superconducting wire and superconducting devices for use in advanced magnet technology, physics research and energy applications. Our diverse customer base includes life science, pharmaceutical, biotechnology and molecular diagnostic research companies, academic institutions, advanced materials and semiconductor industries and government agencies. We maintain major technical and manufacturing centers in Europe, North America and Japan and we have sales offices located throughout

 

17



Table of Contents

 

the world. Our corporate headquarters are located in Billerica, Massachusetts.

 

Our business strategy is to capitalize on our ability to innovate and generate rapid revenue performance, both organically and through acquisitions. Our revenue growth strategy, combined with anticipated improvements to our gross profit margins and increased leverage on our research and development, sales and marketing and distribution investments and general and administrative expenses, is expected to enhance our operating margins and improve our earnings in the future.

 

On May 19, 2010, we completed our acquisition of three former Varian product lines which Agilent divested in connection with obtaining regulatory approval for its May 14, 2010 acquisition of Varian. The Company acquired certain assets and assumed certain liabilities in Varian’s inductively coupled plasma mass spectrometry instruments business, laboratory gas chromatography instruments business, and gas chromatography triple-quadrupole mass spectrometry instruments business (collectively, the “chemical analysis business”). The chemical analysis business complements our existing mass spectrometry products and expands our offerings to industrial and applied markets and provides opportunities to supply customers with equipment packages that have a broader range of applications and value.

 

We are organized into five operating segments, representing each of our five divisions: Bruker AXS, Bruker BioSpin, Bruker Daltonics, Bruker Optics and Bruker Energy & Supercon Technologies. Bruker AXS is in the business of manufacturing and distributing advanced X-ray, spark-optical emission spectroscopy and atomic force microscopy instrumentation used in non-destructive molecular and elemental analysis. Bruker BioSpin is in the business of manufacturing and distributing enabling life science tools based on magnetic resonance technology. Bruker Daltonics is in the business of manufacturing and distributing mass spectrometry instruments that can be integrated and used along with other analytical instruments, as well as our CBRNE detection products. Bruker Optics is in the business of manufacturing and distributing research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. Bruker Energy & Supercon Technologies is in the business of developing and producing superconductivity-based materials and superconductivity-enabled devices.

 

We have combined the Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics operating segments into the Scientific Instruments reporting segment because each has similar economic characteristics, product processes and services, types and classes of customers, methods of distribution and regulatory environments. As such, management reports its results based on the following segments:

 

·                  Scientific Instruments.  The operations of this segment include the design, manufacture and distribution of advanced instrumentation and automated solutions based on X-ray technology, spark-optical emission spectroscopy technology, atomic force microscopy, magnetic resonance technology, mass spectrometry technology and infrared and Raman molecular spectroscopy technology. Typical customers of the Scientific Instruments segment include pharmaceutical, biotechnology and diagnostic companies; academic institutions; medical schools; other non-profit organizations; clinical microbiology laboratories; government departments and agencies; nanotechnology, semiconductor, chemical, cement, metals and petroleum companies; and food, beverage and agricultural analysis companies and laboratories.

 

·                  Energy & Supercon Technologies.  The operations of this segment include the development and marketing of superconducting and non-superconducting materials and devices for growing markets in renewable energy, energy infrastructure, healthcare and “big science” research. This segment supplies low temperature superconductors for use in magnetic resonance imaging and nuclear magnetic resonance systems, fusion energy research and other applications, as well as high temperature superconductors which are primarily used in fusion energy research. This segment also provides superconductivity-enabled devices, such as magnets, accelerator cavities and modules, radio frequency power couplers and linear accelerators, primarily for use in fusion research and other scientific applications. In addition, this segment has a number of devices and materials under development, including superconducting crystal growth magnets for photovoltaic and semiconductor applications, inductive superconducting fault current limiters for energy infrastructure applications and high temperature superconductors for compact high-power wind turbine generators and other applications. Typical customers of the Energy & Supercon Technologies segment include manufacturers of medical technology and life science analytics tools and universities and dedicated research facilities in the fields of material sciences, energy, biotechnology and proteomics, among others.

 

Financial Overview

 

For the three months ended June 30, 2010, our revenue increased by $48.4 million, or 19.2%, to $300.9 million, compared

 

18



Table of Contents

 

to $252.5 million for the comparable period in 2009. Included in this change in revenue is a decrease of approximately $5.9 million from the impact of foreign exchange due to the strengthening of the U.S. Dollar versus the Euro and other foreign currencies and an increase of approximately $3.7 million attributable to acquisition. Excluding the effect of foreign exchange and acquisition, revenue increased by $50.6 million, or 20.0%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $44.5 million, or 18.4%, and the Energy & Supercon Technologies segment, which increased by $5.6 million, or 40.9%. Revenue in the Scientific Instruments segment reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. Revenues in the Energy & Supercon Technologies segment increased due to higher demand for low temperature superconducting wire.

 

For the six months ended June 30, 2010, our revenue increased by $95.6 million, or 19.8%, to $578.6 million, compared to $483.0 million for the comparable period in 2009. Included in this change in revenue is an increase of approximately $12.8 million from the impact of foreign exchange due to the weakening of the U.S. Dollar versus the Euro and other foreign currencies and $10.5 million attributable to acquisition. Excluding the effect of foreign exchange and acquisition, revenue increased by $72.3 million, or 15.0%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $63.7 million, or 13.7%, and the Energy & Supercon Technologies segment, which increased by $10.3 million, or 47.2%. Revenue in the Scientific Instruments segment reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. Revenues in the Energy & Supercon Technologies segment increased due to higher demand for low temperature superconducting wire.

 

The mix of products sold in the Scientific Instruments segment in the three and six months ended June 30, 2010 reflects increased demand from academic, government and industrial customers. We attribute the increase in sales of magnetic resonance and mass spectrometry products and spending by academic and government customers to our new product introductions over the last twelve to eighteen months and to stimulus packages implemented by governments of various countries, including the U.S., Germany, Japan and China. The improvement in revenues from our industrial customers continues to reflect an ongoing improvement in these markets. We remain optimistic that the industrial markets we serve will continue to improve but we will continue to monitor the recovery in these markets. We are also monitoring the developments in academic and government research budgets, primarily in Europe. While many European governments have announced their intentions to reduce overall spending, we believe that funding for the majority of our products and markets will remain stable, or grow in some cases, in most of our key European markets.

 

Income from operations for the three months ended June 30, 2010 was $37.9 million, resulting in an operating margin of 12.6%, compared to income from operations of $20.2 million, resulting in an operating margin of 8.0%, for the comparable period in 2009. The increase in operating margin is primarily the result of the higher revenue described above and the corresponding improvement in our gross profit margins. Our gross profit margin for the second quarter of 2010 was 45.1%, compared with 44.0% for the comparable period in 2009. Higher gross profit margins resulted primarily from changes in product mix, specifically an increase in revenues from high-end instrumentation, including our newly introduced products which were designed to carry higher gross margins than our previous generations of products and the weakening of the Euro, which favorably impacts our gross profit margins as a majority of our production is performed in Europe. The increase in revenue allowed us to better utilize our production facilities and leverage our fixed production costs. The increase in revenue also allowed us to leverage our selling, general and administrative costs and our research and development costs, which decreased to 31.6% of revenue for the three months ended June 30, 2010 compared with 36.2% of revenue for the comparable period of 2009.

 

Income from operations for the six months ended June 30, 2010 was $64.8 million, resulting in an operating margin of 11.2%, compared to income from operations of $34.5 million, resulting in an operating margin of 7.1%, for the comparable period in 2009. The increase in operating margin is primarily the result of higher revenue described above and the corresponding improvement in our gross profit margins. Our gross profit margin as a percentage of revenue was 45.3% for the first half of 2010 and 44.3% for the comparable period in 2009. Higher gross profit margins resulted primarily from changes in product mix, specifically an increase in revenues from high-end instrumentation, including our newly introduced products which were designed to carry higher gross margins than our previous generations of products. The increase in revenue allowed us to better utilize our production facilities and leverage our fixed production costs. The increase in revenue also allowed us to leverage our selling, general and administrative costs and our research and development costs, which decreased to 33.5% of revenue for the six months ended June 30, 2010 compared with 37.1% of revenue for the comparable period of 2009.

 

We incurred approximately $2.8 million of interest expense during the six months ended June 30, 2010 compared to $4.4

 

19



Table of Contents

 

million for the comparable period in 2009. Of the total interest expense incurred in the first half of 2010, approximately $2.4 million related to a credit facility that we entered into during the first quarter of 2008. We initially borrowed $351.0 million under this credit facility in order to finance the acquisition of Bruker BioSpin. In the first half of 2010, we repaid approximately $9.4 million of the amounts outstanding under this credit agreement and, from the inception of this agreement, we have reduced the net amount outstanding by approximately $229.1 million.

 

Our effective tax rate for the three months ended June 30, 2010 was 32.0%, compared to 26.6% for the comparable period in 2009. Our effective tax rate for the six months ended June 30, 2010 was 35.5%, compared to 32.8% for the comparable period in 2009. The change in our effective tax rate relates primarily to the amount and mix of income and taxes outside the U.S. because we are not able to record a tax benefit on losses incurred in the U.S.

 

Our net income attributable to the shareholders of Bruker Corporation for the three months ended June 30, 2010 was $22.6 million, or $0.14 per diluted share, compared to $12.9 million, or $0.08 per diluted share, for the comparable period in 2009. Our net income attributable to the shareholders of Bruker Corporation for the six months ended June 30, 2010 was $38.7 million, or $0.23 per diluted share, compared to $21.3 million, or $0.13 per diluted share, for the comparable period in 2009.

 

CRITICAL ACCOUNTING POLICIES

 

This discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates and judgments, including those related to revenue recognition, income taxes, allowance for doubtful accounts, inventories, goodwill, other intangible assets and long-lived assets, warranty costs and derivative financial instruments. We base our estimates and judgments on historical experience, current market and economic conditions, industry trends and other assumptions that we believe are reasonable and form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

We believe the following critical accounting policies to be both those most important to the portrayal of our financial position and results of operations and those that require the most subjective judgment.

 

Revenue recognition. We recognize revenue from system sales when persuasive evidence of an arrangement exists, the price is fixed or determinable, title and risk of loss has been transferred to the customer and collectability of the resulting receivable is reasonably assured. Title and risk of loss generally are transferred to the customer upon receipt of a signed customer acceptance form for a system that has been shipped, installed, and for which the customer has been trained. As a result, the timing of customer acceptance or readiness could cause our reported revenues to differ materially from expectations. When products are sold through an independent distributor or a strategic distribution partner who assumes responsibility for installation, we recognize the system sale when the product has been shipped and title and risk of loss have been transferred to the distributor. Our distributors do not have price protection rights or rights of return; however, our products are typically warranted to be free from defect for a period of one year. Revenue is deferred until cash is received when collectability is not reasonably assured, such as when a significant portion of the fee is due over one year after delivery, installation and acceptance of a system. For arrangements with multiple elements, we recognize revenue for each element based on the relative fair value of the elements, provided all other criteria for revenue recognition have been met. The fair value for each element provided in multiple element arrangements is typically determined by referencing the prices charged when the element is sold separately. If there is objective and reliable evidence of the fair value of the undelivered items in an arrangement, but no such evidence for the delivered items, we use the residual method to allocate the arrangement consideration. Changes in our ability to establish the fair value for each element in multiple element arrangements could affect the timing of revenue recognition. Revenue from accessories and parts is recognized upon shipment and service revenue is recognized as the services are performed. We also have contracts for which we apply the percentage-of-completion method for revenue recognition. Application of the percentage-of-completion method requires us to make reasonable estimates of the extent of progress toward completion of the contract and the total costs we will incur under the contract. Changes in our estimates could affect the timing of revenue recognition. Grant revenue is recognized when we complete the services required under the grant.

 

Income taxes. The determination of income tax expense requires us to make certain estimates and judgments concerning

 

20



Table of Contents

 

the calculation of deferred tax assets and liabilities, as well as the deductions, carryforwards and credits that are available to reduce taxable income. Deferred tax assets and liabilities arise from differences in the timing of the recognition of revenue and expenses for financial statement and tax purposes. Deferred tax assets and liabilities are measured using the tax rates in effect for the year in which these temporary differences are expected to be settled. We estimate the degree to which tax assets and loss carryforwards will result in a benefit based on expected profitability by tax jurisdiction, and we provide a valuation allowance for tax assets and loss carryforwards that we believe will more likely than not go unused. If it becomes more likely than not that a tax asset or loss carryforward will be used for which a reserve has been provided, we reverse the related valuation allowance. If our actual future taxable income by tax jurisdiction differs from estimates, additional allowances or reversals of reserves may be necessary. In addition, we only recognize benefits for tax positions that we believe are more likely than not of being sustained upon review by a taxing authority with knowledge of all relevant information. We reevaluate our uncertain tax positions on a quarterly basis and any changes to these positions as a result of tax audits, tax laws or other facts and circumstances could result in additional charges to operations.

 

Allowance for doubtful accounts. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to pay amounts due. If the financial condition of our customers were to deteriorate, reducing their ability to make payments, additional allowances would be required, resulting in a charge to operations.

 

Inventories. Inventories are stated at the lower of cost or market, with costs determined by the first-in, first-out method for a majority of subsidiaries and by average cost for certain international subsidiaries. We record provisions to account for excess and obsolete inventory to reflect the expected non-saleable or non-refundable inventory based on an evaluation of slow moving products. Inventories also include demonstration units located in our demonstration laboratories or installed at the sites of potential customers. We consider our demonstration units to be available for sale. We reduce the carrying value of demonstration inventories for differences between cost and estimated net realizable value, taking into consideration usage in the preceding twelve months, expected demand, technological obsolescence and other information including the physical condition of the unit. If ultimate usage or demand varies significantly from expected usage or demand, additional write-downs may be required, resulting in additional charges to operations.

 

Goodwill, other intangible assets and other long-lived assets. We evaluate whether goodwill is impaired annually and when events occur or circumstances change. We test goodwill for impairment at the reporting unit level (the operating segment or one level below an operating segment). The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. We generally determine the fair value of our reporting units using an income approach methodology of valuation that includes the discounted cash flow method. Estimating the fair value of the reporting units requires significant judgments by management about the future cash flows. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, we perform the second step of the goodwill impairment test to measure the amount of the impairment. In the second step of the goodwill impairment test we compare the implied fair value of the reporting unit’s goodwill with the carrying value of that goodwill. We also review finite-lived intangible assets and other long-lived assets when indication of potential impairment exists, such as a significant reduction in undiscounted cash flows associated with the assets. Should the fair value of our long-lived assets decline because of reduced operating performance, market declines, or other indicators of impairment, a charge to operations for impairment may be necessary.

 

Warranty costs. We normally provide a one year parts and labor warranty with the purchase of equipment. The anticipated cost for this warranty is accrued upon recognition of the sale based on historical warranty rates and our assumptions of future warranty claims. The warranty accrual is included as a current liability on the consolidated balance sheets. Although our products undergo quality assurance and testing procedures throughout the production process, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Although our actual warranty costs have historically been consistent with expectations, to the extent warranty claim activity or costs associated with servicing those claims differ from our estimates, revisions to the warranty accrual may be required.

 

Derivative financial instruments. All derivative instruments are recorded as assets or liabilities at fair value, which is calculated as an estimate of the future cash flows, and subsequent changes in a derivative’s fair value are recognized in income, unless specific hedge accounting criteria are met. Changes in the fair value of a derivative that is highly effective and designated as a cash flow hedge are recognized in accumulated other comprehensive income until the forecasted transaction occurs or it becomes probable that the forecasted transaction will not occur. We perform an assessment at the inception of the hedge and on a quarterly basis thereafter, to determine whether our derivatives are highly effective in offsetting changes in the

 

21



Table of Contents

 

value of the hedged items. Any changes in the fair value resulting from hedge ineffectiveness are immediately recognized as income or expense.

 

RESULTS OF OPERATIONS

 

Three Months Ended June 30, 2010 compared to the Three Months Ended June 30, 2009

 

Consolidated Results

 

The following table presents our results for the three months ended June 30, 2010 and 2009 (dollars in millions, except per share data):

 

 

 

Three Months Ended

 

 

 

June 30,

 

 

 

2010

 

2009

 

Product revenue

 

$

267.0

 

$

222.9

 

Service revenue

 

32.5

 

28.3

 

Other revenue

 

1.4

 

1.3

 

Total revenue

 

300.9

 

252.5

 

 

 

 

 

 

 

Cost of product revenue

 

149.1

 

125.2

 

Cost of service revenue

 

16.1

 

16.1

 

Total cost of revenue

 

165.2

 

141.3

 

Gross profit

 

135.7

 

111.2

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

Selling, general and administrative

 

64.0

 

60.4

 

Research and development

 

31.2

 

31.1

 

Amortization of acquisition-related intangible assets

 

0.7

 

0.5

 

Other charges (credits), net

 

1.9

 

(1.0

)

Total operating expenses

 

97.8

 

91.0

 

Operating income

 

37.9

 

20.2

 

 

 

 

 

 

 

Interest and other income (expense), net

 

(4.2

)

(2.9

)

Income before income taxes and noncontrolling interest in consolidated subsidiaries

 

33.7

 

17.3

 

Income tax provision

 

10.8

 

4.6

 

Consolidated net income

 

22.9

 

12.7

 

Net income (loss) attributable to noncontrolling interest in consolidated subsidiaries

 

0.3

 

(0.2

)

Net income attributable to Bruker Corporation

 

$

22.6

 

$

12.9

 

 

 

 

 

 

 

Net income per common share attributable to Bruker Corporation shareholders:

 

 

 

 

 

Basic and diluted

 

$

0.14

 

$

0.08

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

Basic

 

164.3

 

163.3

 

Diluted

 

165.8

 

164.7

 

 

Revenue

 

For the three months ended June 30, 2010, our revenue increased by $48.4 million, or 19.2%, to $300.9 million, compared to $252.5 million for the comparable period in 2009. Included in this change in revenue is a decrease of approximately $5.9 million from the impact of foreign exchange due to the strengthening of the U.S. Dollar versus the Euro and other foreign currencies and an increase of approximately $3.7 million attributable to acquisition. Excluding the effect of foreign exchange

 

22



Table of Contents

 

and acquisition, revenue increased by $50.6 million, or 20.0%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $44.5 million, or 18.4%, and the Energy & Supercon Technologies segment, which increased by $5.6 million, or 40.9%. Revenue in the Scientific Instruments segment reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. Revenues in the Energy & Supercon Technologies segment increased due to higher demand for low temperature superconducting wire.

 

The mix of products sold in the Scientific Instruments segment reflects increased demand from academic, government and industrial customers. We attribute the increase in sales of magnetic resonance and mass spectrometry products and spending by academic and government customers to our new product introductions over the last twelve to eighteen months and to stimulus packages implemented by governments of various countries, including the U.S., Germany, Japan and China. The improvement in revenues from our industrial customers continues to reflect an ongoing improvement in these markets. We remain optimistic that the industrial markets we serve will continue to improve but we will continue to monitor the recovery in these markets. We are also monitoring academic and government research budgets, primarily in Europe. While many European governments have announced their intentions to reduce overall spending, we believe that funding for the majority of our products and markets will remain stable, or grow in some cases, in most of our key European markets.

 

Cost of Revenue

 

Our cost of product and service revenue for the three months ended June 30, 2010, was $165.2 million, resulting in a gross profit margin of 45.1%, compared to cost of product and service revenue of $141.3 million, resulting in a gross profit margin of 44.0%, for the comparable period in 2009. Higher gross profit margins resulted primarily from changes in product mix, specifically an increase in revenues from high-end instrumentation, including our newly introduced products which were designed to carry higher gross margins than our previous generations of products and the weakening of the Euro, which favorably impacts our gross profit margins as a majority of our production is performed in Europe. The increase in revenue also allowed us to better utilize our production facilities and leverage our fixed production costs. We also reduced production costs through various cost saving initiatives.

 

Selling, General and Administrative

 

Our selling, general and administrative expense for the three months ended June 30, 2010 increased to $64.0 million, or 21.3% of revenue, from $60.4 million, or 23.9% of revenue, for the comparable period in 2009. The increase in selling, general and administrative expense is attributable to increases in headcount in support of our revenue growth and acquisitions. Increases in selling, general and administrative expenses were offset, in part, by changes in foreign currency exchange rates, primarily the Euro.

 

Research and Development

 

Our research and development expense for the three months ended June 30, 2010 increased to $31.2 million, or 10.4% of revenue, and was essentially flat compared with research and development expense of $31.1 million, or 12.3% of revenue, for the comparable period in 2009. Research and development expenses increased in the second quarter of 2010 compared with the second quarter of 2009 as a result of increases in headcount in support of new product development and acquisitions; however, these increases were offset by changes in foreign currency exchange rates, primarily the Euro, as the majority of our research and development is preformed in Europe.

 

Amortization of Acquisition-Related Intangible Assets

 

Our amortization expense from acquisition-related intangible assets was $0.7 million for the three months ended June 30, 2010 compared with $0.5 million for the comparable period in 2009. The increase in amortization expense relates to intangible assets acquired in connection with the chemical analysis business from Agilent.

 

Other Charges (Credits), Net

 

Other charges (credits), net of $1.9 million in the second quarter of 2010 related entirely to the Scientific Instruments segment and include a loss of $1.0 million associated with the sale of our investment in Bruker Baltic Ltd., a manufacturing site located in Riga, Latvia that was engaged in the production of certain components used in our X-ray product lines. We

 

23



Table of Contents

 

divested this business as part of our broader corporate strategy of reducing costs and consolidating critical production and know-how in certain key production sites. In addition, other charges (credits), net in the second quarter of 2010 includes $0.5 million of transition-related costs and $0.4 million of acquisition-related costs incurred in connection with our acquisition of the chemical analysis business from Agilent.

 

Acquisition-related credits of $(1.0) million in the second quarter of 2009 relate entirely to the Energy and Supercon Technologies segment and include a bargain purchase gain of $2.1 million recorded in connection with the acquisition of the research instruments business from Varian Medical Systems, Inc. offset, in part, by $0.4 million of transaction costs incurred in connection with the acquisition of the research instruments business and $0.7 million of impairment charges associated with certain fixed assets used in the production of certain superconducting wire.

 

Interest and Other Income (Expense), Net

 

Interest and other income (expense), net during the three months ended June 30, 2010 was $(4.2) million, compared to $(2.9) million for the comparable period of 2009.

 

During the three months ended June 30, 2010, the major components within interest and other income (expense), net were realized and unrealized losses on foreign currency transactions of $2.4 million and net interest expense of $1.1 million. During the three months ended June 30, 2009, the major component within interest and other income (expense), net, were net interest expense of $1.7 million and realized and unrealized losses on foreign currency transactions of $0.7 million.

 

The decrease in interest expense is a function of lower outstanding debt, as we reduced our total debt by $11.0 million in the first half of 2010. Losses on foreign currency exchange rates in the second quarter of 2010 were primarily a function of changes in exchange rates between the Euro and the Swiss Franc.

 

Income Tax Provision

 

Our effective tax rate generally reflects our tax provision for non-U.S. entities only since no benefit was recognized for losses incurred in the U.S. We will maintain a full valuation allowance against all U.S. deferred tax assets, including our U.S. net operating losses and tax credits, until evidence exists that it is more likely than not that the loss carryforward and credit amounts will be utilized to offset U.S. taxable income. Our tax rate may change over time as the amount and mix of income and taxes outside the U.S. changes. The effective tax rate is calculated using our projected annual pre-tax income or loss and is affected by tax credits, the expected level of other tax benefits, and the impact of changes to the valuation allowance, as well as changes in the mix of our pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

 

The income tax provision for the three months ended June 30, 2010, was $10.8 million compared to $4.6 million for the three months ended June 30, 2009, representing effective tax rates of 32.0% and 26.6%, respectively. This change in our effective tax rate relates primarily to the amount and mix of income and taxes outside of the U.S.

 

Net Income (Loss) Attributable to Noncontrolling Interests

 

Net income (loss) attributable to noncontrolling interests for the three months ended June 30, 2010 was $0.3 million compared to $(0.2) million for the comparable period of 2009. Net income (loss) attributable to noncontrolling interests represents the minority shareholders’ proportionate share of the net income (loss) recorded by five majority-owned indirect subsidiaries, Bruker Baltic Ltd., Bruker Labmate Pvt. Ltd., InCoaTec GmbH and Perch Solutions OY, which are included in the Scientific Instruments segment, and RI Research Instruments GmbH, which is included in the Energy & Supercon Technologies segment.

 

Net Income Attributable to Bruker Corporation

 

Our net income for the three months ended June 30, 2010, was $22.6 million, or $0.14 per diluted share, compared to $12.9 million, or $0.08 per diluted share for the comparable period in 2009.

 

24



Table of Contents

 

Segment Results

 

Revenue

 

The following table presents revenue, change in revenue and revenue growth by reportable segment for the three months ended June 30, 2010 and 2009 (dollars in millions):

 

 

 

Three Months Ended June 30,

 

Dollar

 

Percentage

 

 

 

2010

 

2009

 

Change

 

Change

 

Scientific Instruments

 

$

284.9

 

$

241.3

 

$

43.6

 

18.1

%

Energy & Supercon Technologies

 

18.1

 

13.7

 

4.4

 

32.1

%

Eliminations (a)

 

(2.1

)

(2.5

)

0.4

 

 

 

 

 

$

300.9

 

$

252.5

 

$

48.4

 

19.2

%

 


(a) Represents product and service revenue between reportable segments.

 

Scientific Instruments Segment Revenues

 

Scientific Instruments segment revenue increased by $43.6 million, or 18.1%, to $284.9 million for the three months ended June 30, 2010, compared to $241.3 million for the comparable period in 2009. Included in this change in revenue is a decrease of approximately $4.6 million from the impact of foreign exchange due to the strengthening of the U.S. Dollar versus the Euro and other foreign currencies and an increase of approximately $3.7 million attributable to acquisition. Excluding the effect of foreign exchange and acquisition, revenue increased by $44.5 million, or 18.4%. The increase in revenue, excluding the effect of foreign exchange and acquisition, reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. The mix of products sold in the Scientific Instruments segment reflects increased demand from academic, government and industrial customers. We attribute the increase in spending by academic and government customers to new product introductions over the last twelve to eighteen months and stimulus packages implemented by governments of various countries, including the U.S., Germany, Japan and China. We also continued to benefit from improvements in the industrial markets that we serve.

 

System revenue and aftermarket revenue as a percentage of total Scientific Instruments segment revenue were as follows during the three months ended June 30, 2010 and 2009 (dollars in millions):

 

 

 

Three Months Ended June 30,

 

 

 

2010

 

2009

 

 

 

Revenue

 

Percentage of
Segment
Revenue

 

Revenue

 

Percentage of
Segment
Revenue

 

System revenue

 

$

231.5

 

81.3

%

$

191.3

 

79.3

%

Aftermarket revenue

 

53.4

 

18.7

%

50.0

 

20.7

%

Total revenue

 

$

284.9

 

100.0

%

$

241.3

 

100.0

%

 

System revenues in the Scientific Instruments segment include X-ray systems, optical emission spectroscopy systems, atomic force microscopy systems, nuclear magnetic resonance systems, magnetic resonance imaging systems, electron paramagnetic imaging systems, mass spectrometry systems, CBRNE detection systems and molecular spectroscopy systems. Aftermarket revenues in the Scientific Instruments segment include accessory sales, consumables, training and services.

 

Energy & Supercon Technologies Segment Revenues

 

Energy & Supercon Technologies segment revenue increased by $4.4 million, or 32.1%, to $18.1 million for the three months ended June 30, 2010, compared to $13.7 million for the comparable period in 2009. Included in this change in revenue is a decrease of approximately $1.2 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 40.9%. The increase in revenue was the result of higher demand for low temperature superconducting wire.

 

System and wire revenue and aftermarket revenue as a percentage of total Energy & Supercon Technologies segment revenue were as follows during the three months ended June 30, 2010 and 2009 (dollars in millions):

 

25



Table of Contents

 

 

 

Three Months Ended June 30,

 

 

 

2010

 

2009

 

 

 

Revenue

 

Percentage of
Segment
Revenue

 

Revenue

 

Percentage of
Segment
Revenue

 

System and wire revenue

 

$

17.6

 

97.2

%

$

13.3

 

97.1

%

Aftermarket revenue

 

0.5

 

2.8

%

0.4

 

2.9

%

Total revenue

 

$

18.1

 

100.0

%

$

13.7

 

100.0

%

 

System and wire revenues in the Energy & Supercon Technologies segment include low and high temperature superconducting wire and superconducting devices, including magnets, linear accelerators and radio frequency cavities. Aftermarket revenues in the Energy & Supercon Technologies segment include accessory sales.

 

Income (Loss) from Operations

 

The following table presents income (loss) from operations and operating margins on revenue by reportable segment for the three months ended June 30, 2010 and 2009 (dollars in millions):

 

 

 

Three Months Ended June 30,

 

 

 

2010

 

2009

 

 

 

Operating
Income (Loss)

 

Percentage of
Segment
Revenue

 

Operating
Income (Loss)

 

Percentage of
Segment
Revenue

 

Scientific Instruments

 

$

40.4

 

14.2

%

$

20.4

 

8.5

%

Energy & Supercon Technologies

 

(1.7

)

(9.4

)%

(0.7

)

(5.1

)%

Corporate, eliminations and other (a)